Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other financing activities (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Other financing activities for 6 consecutive years, with -$5.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Other financing activities changed N/A to -$5.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $75000.0, a 47.06% increase, with the full-year FY2024 number at $16000.0, down 90.0% from a year prior.
  • Other financing activities was -$5.5 million for Q3 2025 at Whitehawk Therapeutics, down from $803000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $9.6 million in Q3 2021 to a low of -$9.6 million in Q4 2021.
  • A 5-year average of $31818.2 and a median of $49000.0 in 2023 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: crashed 102.94% in 2024, then soared 4623.53% in 2025.
  • Whitehawk Therapeutics' Other financing activities stood at -$9.6 million in 2021, then skyrocketed by 101.03% to $99000.0 in 2022, then crashed by 65.66% to $34000.0 in 2023, then plummeted by 102.94% to -$1000.0 in 2024, then tumbled by 554800.0% to -$5.5 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Other financing activities are -$5.5 million (Q3 2025), $803000.0 (Q2 2025), and $4.8 million (Q1 2025).